Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome
Open Access
- 25 January 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 111 (3), 343-348
- https://doi.org/10.1161/01.cir.0000153272.48711.b9
Abstract
Background— The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction. We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome. Methods and Results— We randomized 58 subjects with the metabolic syndrome in a double-blinded manner to irbesartan 150 mg/d (n=14), lipoic acid 300 mg/d (n=15), both irbesartan and lipoic acid (n=15), or matching placebo (n=14) for 4 weeks. Endothelium-dependent and -independent flow-mediated vasodilation was determined under standard conditions. Plasma levels of interleukin-6, plasminogen activator-1, and 8-isoprostane were measured. After 4 weeks of therapy, endothelium-dependent flow-mediated vasodilation of the brachial artery was increased by 67%, 44%, and 75% in the irbesartan, lipoic acid, and irbesartan plus lipoic acid groups, respectively, compared with the placebo group. Treatment with irbesartan and/or lipoic acid was associated with statistically significant reductions in plasma levels of interleukin-6 and plasminogen activator-1. In addition, treatment with irbesartan or irbesartan plus lipoic acid decreased 8-isoprostane levels. No significant changes in blood pressure were noted in any of the study groups. Conclusions— Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis.Keywords
This publication has 23 references indexed in Scilit:
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Jama-Journal Of The American Medical Association, 2001
- Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cellsAtherosclerosis, 2001
- Novel mechanisms linking angiotensin II and early atherogenesisJournal of the Renin-Angiotensin-Aldosterone System, 2000
- Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?The American Journal of Cardiology, 1999
- Macrophages and atherosclerotic plaque stabilityCurrent Opinion in Lipidology, 1996
- Lipoic and Dihydrolipoic Acids as Antioxidants. a Critical EvaluationFree Radical Research, 1994
- The status of PAI-1 as a risk factor for arterial and thrombotic disease: A reviewAtherosclerosis, 1992
- Thioctic Acid and Dihydrolipoic Acid are Novel Antioxidants Which Interact With Reactive Oxygen SpeciesFree Radical Research Communications, 1991